Wall Street Live — Thursday, October 29
07:55 AM — Eli Lilly (LLY) raised its 2026 revenue outlook to $91–$92 billion on surging demand for Mounjaro and Zepbound. Q3 results topped expectations despite a trim to profit guidance.
This post is for paying subscribers only
Already have an account? Sign in.